相关实验视频

Updated: Jun 9, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

在TP53突变的AML和MDS中整体存活率

Christian J Puzo¹, Karl M Hager², Henry M Rinder²

¹Yale School of Medicine, New Haven, CT, USA.

Annals of hematology

|October 23, 2024

概括

在AML和MDS中,TP53突变会影响存活率. 更新的2022指南对这些病例进行了分类,但预后预测因素仍然不清楚. 这项研究发现TP53变异基因频率和血小板缺血,而不是血清细胞数量,显著预测整体存活率.

科学领域:

血液学血液学血液学
在瘤学瘤学.
遗传学遗传学是一个

背景情况:

TP53突变在急性髓性白血病 (AML) 和骨髓发育综合征 (MDS) 中很常见,通常表明预后不佳.
更新的2022年国际共识分类 (ICC) 和世界卫生组织 (WHO) 准则分类p53-突变的AML/MDS.
根据这些新指南,TP53突变的预后影响,包括共突变及其对整体存活时间 (OS) 的影响,需要进一步调查.

研究的目的:

根据2022年ICC和WHO分类标准,评估AML和MDS患者TP53突变的预后意义.
在这个患者队列中确定整体生存 (OS) 的关键临床和分子预测因素.

主要方法:

在耶鲁纽黑文医院 (2015-2023) 通过下一代测序 (NGS) 确定了210名AML或MDS突变患者的回顾性图表审查.
根据2022年ICC和WHO指导方针对患者的分类.
使用卡普兰-梅尔曲线,日志级别测试和考克斯比例危险模型来分析临床/分子数据和OS之间的关联.

主要成果:

多击TP53突变与MDS中较差的OS相关 (WHO:p=.02;ICC:p=.01) 但不是AML.
最强的预测器是血小板计数<50K (HR:2.01) 和TP53变体等位基因频率 (VAF) ≤40% (HR:0.68).
爆发数,复杂的型和特定的TP53突变特征没有显示与OS的显著关联.

结论:

在根据2022年ICC/WHO标准分类的队列中,TP53VAF和血小板狭窄是AML/MDS中OS的显著预测因素.
这些发现表明,VAF和血小板计数比爆细胞计数或TP53突变特征更为关键的预后指标.
结果强调了更新的标准在识别具有侵略性疾病生物学和不良预后的患者时的有用性.

关键词:

在AML,AML就是AML.国际刑事法庭国际刑事法庭国际刑事法庭国际刑事法庭在 MDS MDS 中.多次击中,多次击中这就是TP53的特点.世界卫生组织WHOWHO

更多相关视频

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...